Shots:Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed
As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones
In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…
